Citation
J Haem Pract 2014; 1(3):J Haem Pract 2014; 1(3): 21-23. doi: 10.17225/jhp00031

Authors: Susan Hook

Susan Hook
Clinical Nurse Specialist in Haemophilia
Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, UK. Email: Susan.Hook@nhslothian.scot.nhs.uk

Abstract

A case study is presented illustrating the everyday challenges faced by patients with haemophilia and inhibitors and how treatment with bypassing agents or just FEIBA prophylaxis can help to control bleeding and improve functional ability.

References

  1. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Treatment Guidelines Working Group. The World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1–14.
  2. Hilgartner MW, Makipernaa A, DiMichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003; 9: 261–8.
  3. Valentino LA. FEIBA prophylaxis for patients with haemophilia and inhibitors. Haemophilia 2006; 12(Suppl. 5): 26–31.
  4. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA©) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 2007; 13: 249–55.
  5. Leissinger C, Gringeri A, Antmen B et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684–92.
  6. Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014; 20: 65-72.
  7. Hoots WK, Ebbesen LS, Konkle BA et al, Novoseven (F7HAEM-1505) Investigators. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008; 14:466–75.
  8. Ekert H, Brewin T, Boey W, et al. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX. Haemophilia 2001; 7: 279–85.
  9. Scalone L, Mantovani LG, Mannucci PM, Gringeri A, COCIS Study Investigators. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154–62.
  10. van Genderen FR, van Meeteren NL, van der Bom JG, Heijnen L, De KP, van den Berg HM, et al. Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia 2004; 10(5): 565-71.
  11. Groen WG, van der Net J, Helders PJ, Fischer K. Development and preliminary testing of a Paediatric Version of the Haemophilia Activities List (PedHAL). Haemophilia 2010; 16: 281-9.
  12. Groen W, Van Der Net J, Lacatusu AM, Serban M, et al. Functional limitations in Romanian children with haemophilia; further testing of psychometric properties of the Paediatric Haemophilia Activities List. Haemophilia 2103; 19: e116-125.

The Journal of Haemophilia Practice is published by Haemnet.

Haemnet is a registered charity that brings together and gives a voice to haemophilia nurses, physiotherapists and allied health care professionals, providing forums for collaborative research, educational activities and support.